NCT02988986View on ClinicalTrials.gov

TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

April 24, 2017

Primary Completion Date

February 1, 2019

Study Completion Date

March 30, 2019

Conditions
Estrogen Receptor Positive Breast Cancer
Interventions
DRUG

TAK-228

MTORC1/2 inhibitor

DRUG

Tamoxifen

Non-steroidal anti-estrogen

Trial Locations (3)

77030

Houston Methodist Hospital, Houston

77070

Houston Methodist Hospital Willowbrook, Houston

77479

Houston Methodist Hospital Sugar Land, Sugar Land

Sponsors
All Listed Sponsors
collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

lead

The Methodist Hospital Research Institute

OTHER